Scholarlink

<p>Bruton tyrosine kinase (BTK), a key component of B-cell receptor signaling, is crucial for the development of B-cell malignancies. Covalent BTK inhibitors (cBTKis), such as ibrutinib, have demonstrated remarkable efficacy, but their curative potential is limited by acquired resistance. Next-generation BTK inhibitors, including non-covalent BTK inhibitors and BTK Proteolysis-targeting chimeras, offer new options for patients who have developed resistance to cBTKis. Some of these inhibitors have shown favorable efficacy and safety profiles, leading to Food and Drug Administration approval. This review summarizes the current landscape of BTK inhibitors, focusing on the evolution from cBTKis to next-generation inhibitors in terms of clinical efficacy and challenges, such as resistance mechanisms and off-target effects. We conclude with an outlook on future research and clinical applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Next-generation Bruton tyrosine kinase inhibitors and degraders in the treatment of B-cell malignancies: advances and challenges

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月28日

查看全文
  • Yao Wang,
  • Yaping Zhang,
  • Jiaqi Liu,
  • Yongning Jiang,
  • Jianyong Li,
  • Wenyu Shi

摘要

Bruton tyrosine kinase (BTK), a key component of B-cell receptor signaling, is crucial for the development of B-cell malignancies. Covalent BTK inhibitors (cBTKis), such as ibrutinib, have demonstrated remarkable efficacy, but their curative potential is limited by acquired resistance. Next-generation BTK inhibitors, including non-covalent BTK inhibitors and BTK Proteolysis-targeting chimeras, offer new options for patients who have developed resistance to cBTKis. Some of these inhibitors have shown favorable efficacy and safety profiles, leading to Food and Drug Administration approval. This review summarizes the current landscape of BTK inhibitors, focusing on the evolution from cBTKis to next-generation inhibitors in terms of clinical efficacy and challenges, such as resistance mechanisms and off-target effects. We conclude with an outlook on future research and clinical applications.